The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market is yet to witness first IDO inhibitor launch and its impact on overall oncology market.
Indoleamine-2,3-dioxygenase (IDO) is one of the many immune checkpoints in tumor immune escape. Inhibiting IDO will help researchers restore immune system responses, which in turn, will help identify and destroy cancer cells. In addition to transforming the approach to treat advanced melanoma, the successful entry of IDO inhibitors in the market will also help transform the treatment of non-small lung cancer, triple-negative breast cancer, and bladder cancer with the existing therapies. Currently, most of the IDO inhibitors under investigation are in the very nascent development stage and focusing on R&D, pharmaceutical companies are making huge investments through collaboration agreements. For instance, one of the major pharmaceutical companies Pfizer has partnered with iTeos Therapeutics for the development of undisclosed IDO1 and tryptophan 2,3-dioxygenase 2 (TDO2) inhibitors.

The global IDO Inhibitors market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on IDO Inhibitors volume and value at global level, regional level and company level. From a global perspective, this report represents overall IDO Inhibitors market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of IDO Inhibitors in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their IDO Inhibitors manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Pfizer
Bristol-Myers Squibb
Kyowa Hakko Kirin
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Dual IDO1/TDO inhibitors
Covalent IDO inhibitors

Segment by Application
Metastatic Melanoma
Metastatic Pancreatic Cancer
mCRPC
Malignant Glioma
Astrocytoma
Breast Cancer